Clinical Trial News

Beigene’s CELESTIAL Trial This clinical trial is for patients who have experienced progression of chronic lymphocytic leukemia.  The usual first line treatment includes a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib , pirtoburtinib) or the combination of venetoclax with obinutuzumab.  Some patients […]

The Beigene’s CELESTIAL clinical trial for chronic lymphocytic leukemia This clinical trial is for patients who have experienced progression of chronic lymphocytic leukemia.  The usual first line treatment includes a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib , pirtoburtinib) or the combination […]

Below is information on the INTerpath 009 study which is a clinical trial for early-stage non-small cell lung cancer (NSCLC). This clinical trial is trying to determine if an investigational study drug combination, when given after initial treatment and surgery, […]

A Phase 3 randomized double-blind study of adjuvant pembrolizumab with or without V940 in participants with resectable Stage II to IIIB (N 2) non-small cell lung cancer who are not achieving pCR after receiving neoadjuvant pembolizumab with platinum-based doublet chemotherapy […]

Chronic Lymphocytic Leukemia (CLL) is a cancer that affects the blood and bone marrow, specifically the white blood cells called lymphocytes. CLL is a chronic leukemia, meaning it develops slowly and can progress slowly over months or years. It is one of the […]

The ECHO Research Department recently hosted Valerie Gabarre, MD (Medical Director) and Berangere Vasseu, MD (Chief Medical Officer) from the French company OSE Immunotherapeutics. OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for […]